Carsten Linneman

Carsten Linnemann, Ph.D., is the President, Chief Executive Officer, and Co-Founder of Neogene Therapeutics. Prior to Neogene, Dr. Linnemann served as Associate Director for Next Generation T Cell Therapies and Managing Director of Kite Pharma. He has co-founded several biotech companies, including T-Cell Factory B.V. Dr. Linnemann has been awarded the Thesis Prize from the Netherlands Society of Gene and Cell Therapy and the Antoni van Leeuwenhoek Career Achievement Award from The Netherlands Cancer Institute. Carsten has various publications in the genetic engineering of T cells and is a pioneer in the human neoantigen biology field.

Dr. Linnemann is an alumnus of the German Academic Foundation and the Boehringer Ingelheim Fonds – Foundation for Biomedical Research. He received a Ph.D. with honors for his work on engineering T cell immunity by TCR gene transfer in the laboratory of Dr. Ton Schumacher at The Netherlands Cancer Institute.